Kim DDH - Search Results

1

Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study.

Pasic I, Moya TA, Remberger M, Chen C, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J. Pasic I, et al. Among authors: kim ddh. Transplant Cell Ther. 2024 Apr 20:S2666-6367(24)00367-1. doi: 10.1016/j.jtct.2024.04.014. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38648898

2

Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation.

Alam N, Marras TK, Atenafu EG, Gupta V, Kuruvilla J, Lipton JH, Messner HA, Kim DD. Alam N, et al. Biol Blood Marrow Transplant. 2012 Dec;18(12):1905-10. doi: 10.1016/j.bbmt.2012.07.012. Epub 2012 Jul 23. Biol Blood Marrow Transplant. 2012. PMID: 22835425 Free article.

3

Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease.

Kim DD, Yun J, Won HH, Cheng L, Su J, Xu W, Uhm J, Gupta V, Kuruvilla J, Messner HA, Lipton JH. Kim DD, et al. Transplantation. 2012 Dec 27;94(12):1250-7. doi: 10.1097/TP.0b013e3182708e7c. Transplantation. 2012. PMID: 23169244

4

A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.

Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim DD, Uhm J, Lambie A, Ellis L, Lipton JH. Shanavas M, et al. Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):87-92. doi: 10.1016/j.clml.2013.09.010. Epub 2013 Oct 1. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24252361

5

Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.

Shanavas M, Messner HA, Kamel-Reid S, Atenafu EG, Gupta V, Kuruvilla J, Kim DD, Uhm J, Lambie A, Ellis L, Lipton JH. Shanavas M, et al. Leuk Lymphoma. 2014 Oct;55(10):2398-401. doi: 10.3109/10428194.2014.882507. Epub 2014 Mar 7. Leuk Lymphoma. 2014. PMID: 24428200 No abstract available.

6

BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.

Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. Kim DD, et al. Am J Hematol. 2014 Jun;89(6):626-32. doi: 10.1002/ajh.23707. Epub 2014 Apr 10. Am J Hematol. 2014. PMID: 24619861 Free article.

7

Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Uhm J, Hamad N, Shin EM, Michelis FV, Shanavas M, Gupta V, Kuruvilla J, Lipton JH, Messner HA, Seftel M, Kim DD. Uhm J, et al. Biol Blood Marrow Transplant. 2014 Nov;20(11):1751-7. doi: 10.1016/j.bbmt.2014.07.001. Epub 2014 Jul 17. Biol Blood Marrow Transplant. 2014. PMID: 25042736 Free article.

8

Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score.

Michelis FV, Messner HA, Uhm J, Alam N, Lambie A, McGillis L, Seftel MD, Gupta V, Kuruvilla J, Lipton JH, Kim DD. Michelis FV, et al. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):e73-81. doi: 10.1016/j.clml.2014.09.014. Epub 2014 Oct 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25458081

9

Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.

Hamad N, Shanavas M, Michelis FV, Uhm J, Gupta V, Seftel M, Kuruvilla J, Lipton JH, Messner HA, Kim DD. Hamad N, et al. Am J Hematol. 2015 May;90(5):392-9. doi: 10.1002/ajh.23955. Epub 2015 Apr 8. Am J Hematol. 2015. PMID: 25615933 Free article.

10

Allogeneic Hematopoietic Stem Cell Transplantions in Blastic Plasmacytoid Dendritic Cell Neoplasm in first complete remission: an effective therapy for a rare disease.

Deotare U, Kim DD, Michelis FV, Lipton JH. Deotare U, et al. Leuk Lymphoma. 2016 Aug;57(8):1942-4. doi: 10.3109/10428194.2015.1115032. Epub 2015 Dec 24. Leuk Lymphoma. 2016. PMID: 26699933 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135 results

Search Page